Company intelligence / Profile preview
Day One Biopharmaceuticals
Brisbane, California, United Statesdayonebio.com ↗
- Ownership
- Public · DAWN
- Development stage
- Commercial
01
Overview
Day One Biopharmaceuticals received FDA approval for OJEMDA™ (tovorafenib) in April 2024 for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The company reported preliminary 2024 OJEMDA™ net product revenue in January 2025 and is advancing multiple clinical programs.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Ipsen Pharma SASMabCare TherapeuticsSprint Bioscience AB
Beyond the preview
Go deeper on Day One Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Day One Biopharmaceuticals.